[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Lymphangioleiomyomatosis (LAM) - Pipeline Insight, 2019

October 2019 | 60 pages | ID: L6E60B52FBB3EN
DelveInsight

US$ 1,000.00 US$ 1,250.00 -20 %
Offer valid until December 31, 2019!

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48 Hours

'Lymphangioleiomyomatosis (LAM) - Pipeline Insight, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lymphangioleiomyomatosis pipeline landscape is provided which includes the disease overview and Lymphangioleiomyomatosis treatment guidelines. The assessment part of the report embraces, in depth Lymphangioleiomyomatosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lymphangioleiomyomatosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Lymphangioleiomyomatosis Understanding

Lymphangioleiomyomatosis (LAM) is a multiple cystic lung disease characterized by progressive cystic destruction of the lung and lymphatic abnormalities, frequently associated with renal angiomyolipomas (AMLs). LAM is a rare progressive multisystem disorder, which occurs either sporadically or as a manifestation of tuberous sclerosis complex (TSC) and predominantly affects women of childbearing age. This specific ailment is characterized by the extent and uncontrolled growth (proliferation) of specialized cells (smooth muscle-like LAM cells) in certain organs of the body, especially lungs, kidney, and lymphatics. It imparts some associated subsets of symptoms such as, coughing and/or difficulty breathing (dyspnea), especially following periods of exercise or exertion. It is also worth mentioning here that the LAM, affected individuals may also experience complications, including the collapse of a lung or fluid accumulation around the lungs (pleural effusion). The disorder is progressive and, in some cases, may result in chronic respiratory failure. Coming to the type-specific forms of LAM, the disease is generally being occurred in two settings, and these settings include tuberous sclerosis complex (TSC-LAM) and sporadic form. LAM that occurs sporadically is called sporadic LAM, and when it occurs in association with a rare disease called tuberous sclerosis complex (TSC), it is being called TSC-LAM.

Lymphangioleiomyomatosis Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in LAM targeted therapeutics development with respective active and dormant or discontinued projects. LAM pipeline report covers 4 + companies. Some of the key players include AstraZeneca (Saracatinib), AI Therapeutics (LAM-001), etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Lymphangioleiomyomatosis Analytical Perspective by DelveInsight
  • In-depth Lymphangioleiomyomatosis Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
  • Lymphangioleiomyomatosis Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

SCOPE OF THE REPORT
  • The Lymphangioleiomyomatosis report provides an overview of therapeutic pipeline activity for Lymphangioleiomyomatosis across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Lymphangioleiomyomatosis therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Lymphangioleiomyomatosis Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Lymphangioleiomyomatosis
REASONS TO BUY
  • Establish a comprehensive understanding of the current pipeline scenario across Lymphangioleiomyomatosis to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Lymphangioleiomyomatosis R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Lymphangioleiomyomatosis in licensing and out licensing strategies by identifying prospective partners with progressing projects for Lymphangioleiomyomatosis to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION

2. LYMPHANGIOLEIOMYOMATOSIS (LAM)

2.1. Lymphangioleiomyomatosis Disease Overview
2.2. Lymphangioleiomyomatosis History
2.3. Lymphangioleiomyomatosis Symptoms
2.4. Lymphangioleiomyomatosis Causes
2.5. Lymphangioleiomyomatosis Pathophysiology
2.6. Lymphangioleiomyomatosis Diagnosis
  2.6.1. Diagnostic Guidelines

3. LYMPHANGIOLEIOMYOMATOSIS CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. LYMPHANGIOLEIOMYOMATOSIS - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Lymphangioleiomyomatosis companies collaborations, Licensing, Acquisition –Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Lymphangioleiomyomatosis Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Lymphangioleiomyomatosis Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
  4.2.1. Assessment by Phase of Development
  4.2.2. Assessment by Product Type (Mono / Combination)
    4.2.2.1. Assessment by Stage and Product Type
  4.2.3. Assessment by Route of Administration
    4.2.3.1. Assessment by Stage and Route of Administration
  4.2.4. Assessment by Molecule Type
    4.2.4.1. Assessment by Stage and Molecule Type
  4.2.5. Assessment by MOA
    4.2.5.1. Assessment by Stage and MOA

5. LYMPHANGIOLEIOMYOMATOSIS PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)
  5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
  5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
  5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
  5.4.1. Comparative Analysis
5.5. Inactive Products

6. LYMPHANGIOLEIOMYOMATOSIS -PRODUCTS ANALYSIS

6.1. Product Profiles
  6.1.1. Saracatinib: AstraZeneca
    6.1.1.1. Product Description
      6.1.1.1.1. Product Overview
      6.1.1.1.2. Mechanism of Action
    6.1.1.2. Research and Development
      6.1.1.2.1. Clinical Studies
        6.1.1.2.1.1. Detailed Study Description
        6.1.1.2.1.2. Study Results
        6.1.1.2.1.3. Clinical Trials: Tabular View
    6.1.1.3. Product Development Activities
      6.1.1.3.1. Tabulated Product Summary
        6.1.1.3.1.1. General Description Table
  6.1.2. LAM-001: AI Therapeutics
    6.1.2.1. Product Description
      6.1.2.1.1. Product Overview
      6.1.2.1.2. Mechanism of Action
    6.1.2.2. Research and Development
      6.1.2.2.1. Clinical Studies
        6.1.2.2.1.1. Detailed Study Description
        6.1.2.2.1.2. Study Results
        6.1.2.2.1.3. Clinical Trials: Tabular View
    6.1.2.3. Product Development Activities
      6.1.2.3.1. Tabulated Product Summary
        6.1.2.3.1.1. General Description Table

7. RECENT TECHNOLOGIES

8. LYMPHANGIOLEIOMYOMATOSIS KEY COMPANIES

8.1. AI Therapeutics (formerly LAM Therapeutics)
8.2. Boehringer Ingelheim
8.3. AstraZeneca
8.4. Merck Sharp & Dohme

9. LYMPHANGIOLEIOMYOMATOSIS KEY PRODUCTS

9.1. LAM
9.2. Nintedanib
9.3. Saracatinib
9.4. Simvastatin

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products
  10.1.1. Reasons for being dormant
10.2. Discontinued Products
  10.2.1. Reasons for the discontinuation

11. LYMPHANGIOLEIOMYOMATOSIS - UNMET NEEDS

12. LYMPHANGIOLEIOMYOMATOSIS - FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research
14.2. Expert Panel Validation

LIST OF TABLES

Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Lymphangioleiomyomatosis Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

LIST OF FIGURES

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Lymphangioleiomyomatosis companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Lymphangioleiomyomatosis Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

KEY COMPANIES

LAM Therapeutics
Novartis
Boehringer Ingelheim
Pfizer
AstraZeneca
Abbott
Merck Sharp & Dohme
Hanmi Pharmaceutical
mondoBIOTECH
Navitor Pharmaceuticals
Recursion Pharmaceuticals
Merck Sharp & Dohme
Genentech




More Publications